Borgen, Elin
Rypdal, Maria C.
Sosa, Maria Soledad
Renolen, Anne
Schlichting, Ellen
Lønning, Per E.
Synnestvedt, Marit
Aguirre-Ghiso, Julio A.
Naume, Bjørn
Funding for this research was provided by:
National Cancer Institute (CA109182)
National Cancer Institute (CA191430, CA196521, CA163131, 22CA201054)
U.S. Department of Defense (BC132674)
U.S. Department of Defense (BC112380)
Samuel Waxman Cancer Research Foundation (na)
Melanoma Research Alliance (NA)
Susan G. Komen (CCR17483357)
The Research Council of Norway (NA)
South-Eastern Norway Regional Health Authority (NA)
Kreftforeningen (NA)
Article History
First Online: 16 October 2018
Ethics approval and consent to participate
: NeoTax Study: Norwegian Regional Ethics Committee approval number 273/96–82.96 REK Helseregion III. Oslo1 Study: Norwegian Regional Ethics Committee approval number S-97103. SATT Study: Norwegian Regional Ethics Committee approval number S-03032. Informed consent to participate was given by all patients.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.